Article
EVA: a Foundation Model Advancing Translational Drug Development in Immuno-Inflammation
2025-05-07
Abstract excerpt
Drug development is a lengthy and high-risk process, with most investigational drug candidates failing in phase II randomized clinical trials (RCT) due to insufficient efficacy. It makes early prediction of trial outcomes crucial for reducing attrition and guiding strategic decisions, especially in immunology and inflammation (I&I) diseases. Herein, we present EVA, the first pre-trained foundation model in complex...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 621b86ce-d6c4-58c9-b271-b065c172a257
- DOI
- 10.1101/2025.05.02.651839
